@SyedMTaufik My English is a little rusty. The expression sometime does not or difficulty to convey my idea. So thank you all for forgiving me expressing in Chinese. Thank you for Google Translate in this era. If anything is unclear, please feel free to discuss.
But there are some things that we cannot say so clearly, because mutual respect is necessary. The market has market rules, have some potential tacit rules of the game. But during the epidemic, many people are forced to hope and get a little benefit from investment for cover the life, why not MarketMaker or Manipulator give a helping hand, should not put people in a difficult position.
If a game of chess is broken, the cost definitely has increased. So sometimes mutual understanding it is important to each other. If you take a long-term perspective, maybe you can make more money!
11th JUNE 2021 – YTB Healthcare Sdn Bhd, a subsidiary of Yong Tai Bhd has today received the first batch of inactivated Covid-19 Vaccine.
The Vaccine was developed by the Group’s strategic partner, Shenzhen Kangtai Biological Products Co., Ltd. (“SZKT”).
The arrival of the Vaccine, which was witnessed by Y.B. Senator Jaziri Alkaf Abdillah Suffian and YTB’s Chief Executive Officer and Executive Director Datuk Wira Boo Kuang Loon.
SZKT’s Vaccine has obtained the Emergency Use Authorisation (“EUA”) granted by the Government of China. SZKT has also commenced its vaccination programme in China, and has been used to vaccinate millions of China citizens since 1 June 2021.
This Phase 3 clinical trial will enrol 3,000 subjects from Malaysia, and the subjects will receive the Vaccine in 2 doses 28 days apart.
Yong Tai is the exclusive distributor for SZKT’s Vaccine with a period of 5 years (renewable) for no less than 20 million doses yearly. “This venture will create a strong income stream and contribute positively to the Group,” Datuk Wira Boo said.
我們來看看昨天「Yong Tai receives first batch of SZKT's vaccine, paves way to launch phase 3 clinical trial in Malaysia」這新聞的發佈時間節點:
June 11, 2021 17:41 pm - theedgemarkets.com 發佈新聞 「Yong Tai receives first batch of SZKT's vaccine, paves way to launch phase 3 clinical trial in Malaysia」
June 11, 2021 18:06 pm - theedgemarkets.com 發佈新聞 「收到深圳康泰生物首批疫苗 永大將在大馬啟動第三期臨床試驗」-
MarketPlayer 發佈英文版 11/06/2021 3:27 PM (15:27 pm)
keatdash73 發佈中文版 11/06/2021 4:00 PM (16:00 pm)
在新聞發佈的時間節點上,MarketPlayer 和 keatdash73 兩位的時間都比 the edge markets 早,且在當下是沒有其他正式新聞被發佈出來的.
所以如果是我誤解了,請 keatdash73 予以包涵和見諒.畢竟你們的動作太快了,在正式新聞發佈前兩個小時就在論壇中發佈新聞稿,而上市公司的新聞發佈是有程序的.如果處理不當,是觸及 Bursa 的管控機制的灰色地帶的.
I may not able to predict share price. Many of you have no idea how long a phase 3 trial needed to take. I can tell you it won’t concluded within 6 months even for emergency approval. With 3 approved vaccines available in Malaysia, finding volunteers is super task now.
Just think how long it will take to get 3000 volunteers? No need to believe me, just walk in to more retail pharmacy, I’m sure you able to get 1-2 pharmacists used to work with NPRA.
268,000 doses of AstraZeneca eaten up in less than 4 hours, even when the government was honest on the risk involved. @sonickid, Be vigilant, Covid19 vaccine is the highly sought after item in 2021.
Kangtai Biological's COVID-19 vaccine gets emergency use approval in China By Reuters Staff
BEIJING (Reuters) - China has given emergency use approval to a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products, the company said on Friday, adding a sixth shot to the country’s vaccination drive.
China has already administered 366.9 million doses to people using five home-made products, three of which adopt a similar technology as the Kangtai shot, where inactivated coronavirus that cannot replicate in human cells is used to trigger an immune response.
Kangtai did not say on Friday what sectors of China’s population its shot could be used in, when use would start or how long the approval will be effective.
A clinical trial record in April said Kangtai aimed to start a Phase III clinical trial this month involving 28,000 participants aged 18 and above to evaluate the efficacy and safety of its two dose-based shot given 28 days apart.
The record, published in the site ClinicalTrials.gov, which is maintained by a department under the National Institute of Health of the United States, did not specify where the trial will take place.
China’s vaccine administration law allows emergency use “within certain scope and time limit” of vaccines during major health crises. A COVID-19 shot from a unit of Chongqing Zhifei Biological Products is also being used in the country under emergency clearance.
Kangtai has also obtained exclusive right to develop and manufacture the vaccine developed by AstraZeneca and Oxford University in mainland China.
Reporting by Roxanne Liu and Meg Shen; Editing by Frances Kerry
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
ceelo87
405 posts
Posted by ceelo87 > 2021-06-10 16:55 | Report Abuse
drop every day. HA HA